// App-Quantinova.ai

4878 : Quantitative cell-based bioassays for therapeutic development targeting immune checkpoint and co-stimulatory receptors

Researchers

Presenter

  • Jamison Grailer

Principal Investigators

  • Pete Stecha

  • Jun Wang

  • Jim Hartnett

  • Frank Fan

  • Mei Cong

  • Zhi-jie Jey Cheng

Medical Centers

  • Promega Corporation, Madison, WI.

Locations

  • United States

Companies

  • Promega Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Natural Killer cells

  • Cluster of Differentiation 40

  • Programmed cell death protein 1

  • Cytotoxic T-lymphocyte-associated protein 4

  • T-cell receptor

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved